Pharmacotherapy of Inflammatory and Pruritic Manifestations of Corticosteroid-Responsive Dermatoses Focus on Clobetasol Propionate

The anti-inflammatory and vasoconstrictive properties of topical corticosteroids (TCs) contribute in providing therapeutic benefits in several skin conditions, including atopic eczema, localized vitiligo, psoriasis, and chronic hand eczema. Clobetasol propionate (CP) is the most common topical agent used for psoriasis management and demonstrates an efficacy superior to other TCs. A new CP 0.025% cream formulation has demonstrated hypoallergenic effects due to the absence of known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers. Lower CP serum levels and less hypothalamic–pituitary–adrenal axis suppression with CP 0.025% cream formulation than with CP 0.05% ensure better safety. The present case series discusses the clinical experience of using CP 0.025% cream in various dermatological conditions.

Section: Discussionmentioning

confidence: 99%

Role of clobetasol propionate 0.025% topical therapy in various dermatoses

Vishwanath¹,

Chaudhary²,

Agarwal

et al. 2021

“…6 Moreover, the 0.025% CP formulation has demonstrated proven efficacy in many other chronic skin diseases, including controlling inflammation and pruritus in various steroidresponsive dermatoses. 2 CP is a highly potent fifthgeneration corticosteroid recommended for the treatment of psoriasis and other corticosteroid-responsive dermatoses. 1,2 Two independent 15-day phase III, randomized, controlled trials demonstrated significantly better primary and secondary endpoint success using CP, 0.025% cream formulation in patients with moderate-to-severe plaque psoriasis compared to the vehicle cream (p<0.001).…”

Section: Discussionmentioning

confidence: 99%

“…2 CP is a highly potent fifthgeneration corticosteroid recommended for the treatment of psoriasis and other corticosteroid-responsive dermatoses. 1,2 Two independent 15-day phase III, randomized, controlled trials demonstrated significantly better primary and secondary endpoint success using CP, 0.025% cream formulation in patients with moderate-to-severe plaque psoriasis compared to the vehicle cream (p<0.001). 1 CP cream, 0.025% significantly reduces body surface area and shows clear or almost clear skin at the end of the 15day treatment in a high percentage of patients with moderate-to-severe plaque psoriasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Topical Corticosteroid Therapy in Various Dermatoses

Singh¹,

Zanwar²,

Kumar

et al. 2021

Topical corticosteroids are the cornerstone in managing several dermatologic disorders, including plaque psoriasis.Managing plaque psoriasis warrants the use of an effective anti-inflammatory, antimitotic, antipruritic, and immunosuppressive agent, such as clobetasol propionate (CP). Recently, CP 0.025% cream received approval by United States food and drug administration (US FDA) for the treatment of moderate-to-severe psoriasis in adult patients. CP 0.025% cream has proven efficacious in chronic skin diseases, including controlling inflammation and pruritus, in various steroid-responsive dermatoses. In contrast to prior CP formulations, this novel CP 0.025% cream formulation does not contain propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers, which are known contact allergens. The other beneficial attributes of this CP 0.025% cream formulation are high penetration of active ingredients and a lower degree of systemic absorption. This case series discusses the experience of using CP 0.025% cream in terms of its efficacy and safety in various dermatologic conditions.

“…2 CP is a fifth-generation corticosteroid and is considered the most potent topical steroid. 3 The new CP 0.025% cream formulation has been approved to be applied twice daily for the treatment of moderate-to-severe psoriasis in adult patients. CP 0.025% cream does not contain known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers, unlike the previous CP formulations (0.05%).…”

Section: Introductionmentioning

confidence: 99%

Treatment with clobetasol propionate 0.025% topical therapy in various dermatoses

Guttedar¹,

Mishra²,

Gupta

et al. 2021

Owing to their anti-inflammatory and vasoconstrictive properties. Topical corticosteroids (TCs) provide benefits in various dermatological conditions, including atopic eczema, psoriasis, chronic hand eczema, and localized vitiligo. Clobetasol propionate (CP) is the most common topical agent possessing anti-inflammatory, antimitotic, antipruritic, and immunosuppressive properties that are employed in the management of plaque psoriasis. CP 0.025% cream was approved by the United States food and drug administration for the treatment of moderate-to-severe psoriasis in adult patients. The formulation is free from known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers, and has demonstrated hypoallergenic effects. High penetration of active ingredients and a lower degree of systemic absorption make CP 0.025% an effective and safe agent. This case series discusses the clinical experience of using CP 0.025% cream in various dermatologic conditions, focusing on its efficacy and safety.